As of 2026-03-06, the EV/EBITDA ratio of Seres Therapeutics Inc (MCRB) is -0.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MCRB's latest enterprise value is 34.99 mil USD. MCRB's TTM EBITDA according to its financial statements is -154.57 mil USD. Dividing these 2 quantities gives us the above MCRB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-03 | -0.21 |
| 2026-03-02 | -0.22 |
| 2026-02-27 | -0.20 |
| 2026-02-26 | -0.21 |
| 2026-02-25 | -0.21 |
| 2026-02-24 | -0.20 |
| 2026-02-23 | -0.17 |
| 2026-02-20 | -0.19 |
| 2026-02-19 | -0.20 |
| 2026-02-18 | -0.17 |
| 2026-02-17 | -0.18 |
| 2026-02-13 | -0.19 |
| 2026-02-12 | -0.17 |
| 2026-02-11 | -0.52 |
| 2026-02-10 | -0.53 |
| 2026-02-09 | -0.55 |
| 2026-02-06 | -0.51 |
| 2026-02-05 | -0.48 |
| 2026-02-04 | -0.49 |
| 2026-02-03 | -0.59 |
| 2026-02-02 | -0.58 |
| 2026-01-30 | -0.57 |
| 2026-01-29 | -0.59 |
| 2026-01-28 | -0.58 |
| 2026-01-27 | -0.60 |
| 2026-01-26 | -0.61 |
| 2026-01-23 | -0.57 |
| 2026-01-22 | -0.59 |
| 2026-01-21 | -0.57 |
| 2026-01-20 | -0.57 |
| 2026-01-16 | -0.63 |
| 2026-01-15 | -0.58 |
| 2026-01-14 | -0.63 |
| 2026-01-13 | -0.63 |
| 2026-01-12 | -0.62 |
| 2026-01-09 | -0.61 |
| 2026-01-08 | -0.60 |
| 2026-01-07 | -0.62 |
| 2026-01-06 | -0.60 |
| 2026-01-05 | -0.58 |
| 2026-01-02 | -0.58 |
| 2025-12-31 | -0.56 |
| 2025-12-30 | -0.54 |
| 2025-12-29 | -0.57 |
| 2025-12-26 | -0.55 |
| 2025-12-24 | -0.59 |
| 2025-12-23 | -0.57 |
| 2025-12-22 | -0.55 |
| 2025-12-19 | -0.57 |
| 2025-12-18 | -0.59 |